World-Class Research Centre
for Personalized Medicine
2 Akkuratova street, St. Petersburg 197341
On July 9-13, the annual international scientific and practical congress "International Society on Thrombosis and Haemostasis (ISTH) 2022" was held in a hybrid format. The Congress, organized by the International Society for Thrombosis and Hemostasis, brings together physicians and researchers involved in the diagnosis and treatment of hematological diseases and thromboembolic events. Within the framework of this congress, issues of the pathophysiology of venous and arterial thrombosis, hemorrhagic complications of anticoagulant therapy, as well as new aspects of the fundamental understanding of blood coagulation factors and the role of platelets in the hemostasis system were observed. Special sections were devoted to achievements and problems in the field of gene therapy, the relationship between the immune system and hemostasis in the formation of a thrombus and it’s resolution, modern aspects of hereditary hemophilia therapy and diagnosis, as well as new ideas about thrombotic complications in the new coronavirus infection COVID-19. Particular attention was attendant to the sessions devoted to the biology of coagulation, the structure and functions of coagulation factors, the relationship between inflammation, primary immunity and thrombus formation, as well as thrombocytes, megakaryocytes and endotheliocytes signaling pathways molecular mechanisms. Of great interest were sections devoted to new achievements in the field of timely diagnosis and prevention of venous thromboembolic events, as well as the principles of managing these patients. The number of reports on cancer-associated thrombosis has increased markedly this year.
Researchers of the Word-Class Research Center for Personalized Medicine this year took part in the congress in an online format. Senior researcher of the Research Group of Cardio-Oncology Melnichnikova O. S. presented the results obtained in the field of studying the mechanisms of venous thrombosis in patients with cancer of the central nervous system. The work is carried out by a multidisciplinary team of researchers, including neurosurgeons, oncologists, cardiologists and doctors of laboratory diagnostics, and is carried out at two sites of the center: the main clinical complex and the Polenov Neurosurgical Institute. The presented poster report "Laboratory assessment of prothrombotic status in patients with primary brain tumors" reflected the first results of the work devoted to the search for predictors of venous thromboembolic events in patients with brain tumors of glial origin. It should be noted that this category of patients has the highest risk of thrombotic complications, while the difficulties of primary prevention and treatment with anticoagulants are associated with high risks of bleeding. The development of an algorithm for risk stratification of the development of venous thrombosis in patients with glioblastomas is one of the tasks of the Research Group of Cardio-Oncology.
The results of the work devoted to the study of the mechanisms of formation of chronic thromboembolic pulmonary hypertension were also presented at the congress. The study is carried out by employees of the Research Institute of Non-Coronary Heart Diseases and the Department of Laboratory Medicine and Genetics with the support of a grant from the Russian Science Foundation (head of the research grant Simakova M. A.). Professor of the Department of Laboratory Medicine and Genetics Sirotkina O.V. presented a poster report "Erythrocyte-derived microvesicles and microRNA-144/451 cluster in patients with post-thromboembolic syndrome", dedicated to the molecular aspects of the transformation of acute pulmonary embolism into post-thrombotic syndrome.
Thus, the ISTH 2022 congress once again brought together the world's leading experts in the field of thrombosis, hemostasis and angiology, becoming a platform for discussing the latest scientific achievements aimed at personalizing the management of patients of various profiles in terms of thromboprophylaxis and translating scientific developments into clinical practice.
Back to the list